Evaluation of the modified diet in renal disease equation for calculation of carboplatin dose

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 235-241

  Shord, Stacy S ^a   Bressler, Linda R ^a   Radhakrishnan, Latha ^a   Chen, Ningyu ^a   Villano, J Lee ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Calvert formula; Carboplatin; Cockcroft Gault formula; Glomerular filtration rate; Jelliffe formula; Modified Diet in Renal Disease

Indexed keywords

CARBOPLATIN; CREATININE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; PACLITAXEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; DOSE CALCULATION; DRUG DOSE COMPARISON; FEBRILE NEUTROPENIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MODIFIED DIET IN RENAL DISEASE EQUATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEOPLASM; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

CARBOPLATIN; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; PLATELET COUNT; RETROSPECTIVE STUDIES;

EID: 60349128645     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L446     Document Type: Article

References (35)

1. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001;84:452-9.
2. 51Cr-EDTA. Clin Sci 1969;37:169-80.
3. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
4. Jelliffe RW. Creatinine clearance: bedside estimate (letter). Ann Intern Med 1973;79:604-5.
5. Donadio C, Lucchesi A, Ardini M, Cosio S, Gadducci A. Renal impairment in patients with ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2003;106:198-202.
6. Donahue A, McCune JS, Faucette S, et al. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. Cancer Chemother Pharmacol 2001;47:373-9.
7. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004;15:291-5.
8. Montgomery MJ, Beringer PM, Louie SG, Gill MA. Estimation of creatinine clearance in patients with metastatic ovarian cancer. Ther Drug Monit 2000;22:695-700.
9. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol 1998;42:307-12.
10. Tsubaki T, Goodin S, Leader WG, Chandler MH. Estimation of creatinine clearance in patients with gynecologic cancer. Clin Pharm 1993;12: 685-90.
11. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1): S1-266.
12. Nagao S, Fujiwara K, Imafuku N, et al. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula. Gynecol Oncol 2005;99:327-33.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
14. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54.
15. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004;141: 929-37.
16. Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982;9:140-7.
17. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
18. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 1985;45(12 pt 1):6502-6.
19. Van Echo DA, Egorin MJ, Whitacre MY, Olman EA, Aisner J. Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. Cancer Treat Rep 1984;68:1103-14.
20. Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984;44:5432-8.
21. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;10:520-8.
22. Cooper AV, Roques TW. Can MDRD (Modification of Diet in Renal Disease) be used to estimate GFR in patients receiving carboplatin (abstract P16)? Clin Oncol (R Coll Radiol) 2007;19(3 suppl):S27.
23. de Lemos ML, Hsieh T, Hamata L, et al. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. Gynecol Oncol 2006;103:1063-9.
24. Poole SG, Dooley MJ, Rischin D. Calculating carboplatin doses using the 4-variable Modification of Diet in Renal Disease (4-v MDRD) estimate of glomerular filtration rate (GFR) in the Calvert formula (abstract 2521). ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(Jun 20 suppl):2521.
25. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098.
26. Thadhani R, Pascual M, Bonventre JV. Acute renal failure (letter). N Engl J Med 1996;334:1448-60.
27. Oguri S, Sakakibara T, Mase H, et al. Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 1988;28:208-15.
28. NCCN practice guidelines in oncology-v1.2009. Myeloid growth factors. National Comprehensive Cancer Network Inc., Fort: Washington, PA, November 6, 2008.
29. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
30. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, N1H, DHHS, March 31, 2003. http://ctep.cancer.gov. Published August 9, 2006 (accessed 2009 Jan 14).
31. Ando M, Minami H, Ando Y, et al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 2000;6:4733-8.
32. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 1996;37:266-70.
33. Childs WJ, Nicholls EJ, Horwich A. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol 1992;3:291-6.
34. Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 2006;12:6502-8.
35. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006;107:506-13.